Man Treated for Non-Existent Lymphoma Files Federal Lawsuit

According to the St. Louis Post-Dispatch, a federal civil suit has been filed in St. Louis by a Florida man who underwent several months of both radiation therapy and chemotherapy at the John Cochran VA Medical Center only to be informed that that he had never had cancer to begin with.

Although details are lacking, it appears the man, Dustin A. Brooks, had been treated for a subtype of lymphoma between July and November of 2009. It wasn't until later the following year that the hospital told him that he never had the disease to begin with, but that he was now at risk of developing cancer on account of the treatments he received.

The suit alleges pain, suffering and mental anguish; he also charges that the treatment made him sterile.

In 2011, Brooks demanded a $750,000 settlement from the Veterans Administration and he rejected a 2012 offer from the VA of $150,000.

Problems related to the Cochran VA facility are not new. For example, in 2010 almost 2,000 veterans were told they might have been exposed to several viruses including HIV due to possible sterilization issues at the hospital. Thus far, no illnesses have been linked to the incident.

Source: St. Louis Post-Dispatch

Photo from NCI; not a picture of the people or institutions mentioned in this story.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap